205 related articles for article (PubMed ID: 23901271)
21. Formulation, Characterization, and Pharmacokinetic Studies of 6-Gingerol-Loaded Nanostructured Lipid Carriers.
Wei Q; Yang Q; Wang Q; Sun C; Zhu Y; Niu Y; Yu J; Xu X
AAPS PharmSciTech; 2018 Nov; 19(8):3661-3669. PubMed ID: 30324361
[TBL] [Abstract][Full Text] [Related]
22. Construction and in vitro/in vivo evaluation of 17-allylamino-17-demethoxygeldanamycin (17AAG)-loaded PEGylated nanostructured lipid carriers.
Wang Z; Wang J; Yang S; Hou S
Drug Dev Ind Pharm; 2016 Jan; 42(1):91-98. PubMed ID: 25853294
[TBL] [Abstract][Full Text] [Related]
23. A new topical formulation for psoriasis: development of methotrexate-loaded nanostructured lipid carriers.
Pinto MF; Moura CC; Nunes C; Segundo MA; Costa Lima SA; Reis S
Int J Pharm; 2014 Dec; 477(1-2):519-26. PubMed ID: 25445970
[TBL] [Abstract][Full Text] [Related]
24. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
25. Targeted Nanostructured Lipid Carrier for Brain Delivery of Artemisinin: Design, Preparation, Characterization, Optimization and Cell Toxicity.
Emami J; Yousefian H; Sadeghi H
J Pharm Pharm Sci; 2018; 21(1s):225s-241s. PubMed ID: 30266137
[TBL] [Abstract][Full Text] [Related]
26. Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers.
Yu G; Ali Z; Sajjad Khan A; Ullah K; Jamshaid H; Zeb A; Imran M; Sarwar S; Choi HG; Ud Din F
Int J Nanomedicine; 2021; 16():3255-3273. PubMed ID: 34012260
[TBL] [Abstract][Full Text] [Related]
27. Nanostructured lipid carriers for the topical delivery of tretinoin.
Ghate VM; Lewis SA; Prabhu P; Dubey A; Patel N
Eur J Pharm Biopharm; 2016 Nov; 108():253-261. PubMed ID: 27519827
[TBL] [Abstract][Full Text] [Related]
28. Nanostructured lipid carriers of pioglitazone for transdermal application: from experimental design to bioactivity detail.
Alam S; Aslam M; Khan A; Imam SS; Aqil M; Sultana Y; Ali A
Drug Deliv; 2016; 23(2):601-9. PubMed ID: 24937378
[TBL] [Abstract][Full Text] [Related]
29. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers.
Rizwanullah M; Amin S; Ahmad J
J Drug Target; 2017 Jan; 25(1):58-74. PubMed ID: 27186665
[TBL] [Abstract][Full Text] [Related]
30. Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting.
Tsai MJ; Wu PC; Huang YB; Chang JS; Lin CL; Tsai YH; Fang JY
Int J Pharm; 2012 Feb; 423(2):461-70. PubMed ID: 22193056
[TBL] [Abstract][Full Text] [Related]
31. Quality by design (QbD)-based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies.
Gurumukhi VC; Bari SB
Drug Deliv Transl Res; 2022 May; 12(5):1230-1252. PubMed ID: 34110597
[TBL] [Abstract][Full Text] [Related]
32. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
33. Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Paudel A; Ameeduzzafar ; Imam SS; Fazil M; Khan S; Hafeez A; Ahmad FJ; Ali A
Curr Drug Deliv; 2017; 14(7):1005-1015. PubMed ID: 28034361
[TBL] [Abstract][Full Text] [Related]
34. Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects.
Dong Z; Iqbal S; Zhao Z
AAPS PharmSciTech; 2020 Jan; 21(2):64. PubMed ID: 31932990
[TBL] [Abstract][Full Text] [Related]
35. Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model.
Sathe P; Saka R; Kommineni N; Raza K; Khan W
Drug Dev Ind Pharm; 2019 May; 45(5):826-838. PubMed ID: 30764674
[TBL] [Abstract][Full Text] [Related]
36. Preparation and in vitro-in vivo evaluation of ofloxacin loaded ophthalmic nano structured lipid carriers modified with chitosan oligosaccharide lactate for the treatment of bacterial keratitis.
Ustündağ-Okur N; Gökçe EH; Bozbıyık Dİ; Eğrilmez S; Ozer O; Ertan G
Eur J Pharm Sci; 2014 Oct; 63():204-15. PubMed ID: 25111119
[TBL] [Abstract][Full Text] [Related]
37. Nanostructured Lipid Carriers for Oral Bioavailability Enhancement of Exemestane: Formulation Design, In Vitro, Ex Vivo, and In Vivo Studies.
Singh A; Neupane YR; Mangla B; Kohli K
J Pharm Sci; 2019 Oct; 108(10):3382-3395. PubMed ID: 31201904
[TBL] [Abstract][Full Text] [Related]
38. Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.
Su Z; Niu J; Xiao Y; Ping Q; Sun M; Huang A; You W; Sang X; Yuan D
Mol Pharm; 2011 Oct; 8(5):1641-51. PubMed ID: 21770405
[TBL] [Abstract][Full Text] [Related]
39. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
[TBL] [Abstract][Full Text] [Related]
40. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
Li H; Chen M; Su Z; Sun M; Ping Q
Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
